Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

Yunnan Baiyao Acquires Two Small Pharmas

publication date: Nov 29, 2007
View a Printer Friendly version of this page, allowing you to print the page.

Yunnan Baiyao Group Co., Ltd. will buy two smaller pharmaceutical companies for a total of 50 million RMB ($6.8 million). Yunnan will pay 37 million RMB ($5 million) for Kunming Xingzhong Pharmaceutical Co. and 13 million RMB ($1.8 million) for Kunming Yunjian Pharmaceutical Co. The reason for the purchase seems to be the added production capacity the acquisitions would bring, because the ongoing business of each company adds only an extremely small fraction onto the business of Yunnan Baiyao, which has a market cap of $2 billion.  More details...

Stock Symbol: (SZSE: 000538)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China